BR0015055A - Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr - Google Patents
Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccrInfo
- Publication number
- BR0015055A BR0015055A BR0015055-0A BR0015055A BR0015055A BR 0015055 A BR0015055 A BR 0015055A BR 0015055 A BR0015055 A BR 0015055A BR 0015055 A BR0015055 A BR 0015055A
- Authority
- BR
- Brazil
- Prior art keywords
- tccr
- understanding
- polypeptides
- mammal
- mediated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
"MéTODO DE AUMENTO, ESTIMULAçãO OU POTENCIALIZAçãO DA DIFERENCIAçãO DE CéLULAS T, MéTODO DE TRATAMENTO DE UMA DOENçA MEDIADA POR TH1 EM UM MAMìFERO, MéTODO DE PREVENIR, INIBIR OU ATENUAR A DIFERENCIAçãO DE CéLULAS T, MéTODO DE TRATAMENTO DE UMA DOENçA MEDIADA POR TH2 EM UM MAMìFERO, MéTODO DE DETERMINAçãO DA PRESENçA DE POLIPEPTìDEO TCCR EM UMA CéLULA, MéTODO DE DIAGNóSTICO DE DOENçAS MEDIADAS POR TH1 OU MEDIADAS POR TH2 EM UM MAMìFERO, MéTODO DE IDENTIFICAçãO DE COMPOSTOS CAPAZES DE INIBIR A EXPRESSãO DE POLIPEPTìDEOS TCCR E MéTODO PARA IDENTIFICAçãO DE COMPOSTOS CAPAZES DE INIBIR A ATIVIDADE BIOLóGICA DE POLIPEPTìDEO TCCR, USO DE ANTAGONISTAS E AGONISTAS DE POLIPEPTìDEOS TCCR". A presente invenção refere-se a métodos de tratamento e diagnóstico de doenças relacionadas com a imunidade, que incluem as doenças mediadas por citoquinas liberadas principalmente por células Th1 ou Th2 em resposta ao estímulo antigênico. A presente invenção refere-se ainda a métodos para induzir a diferenciação de células T tanto no subtipo Th1 ou no subtipo Th2, com base nos níveis de expressão relativos do gene TCCR e seus agonistas ou antagonistas. A presente invenção refere-se ainda a um método de diagnóstico de doenças mediadas por Th1 e Th2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16054299P | 1999-10-20 | 1999-10-20 | |
PCT/US2000/028827 WO2001029070A2 (en) | 1999-10-20 | 2000-10-18 | Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0015055A true BR0015055A (pt) | 2002-07-16 |
Family
ID=22577314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0015055-0A BR0015055A (pt) | 1999-10-20 | 2000-10-18 | Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr |
Country Status (13)
Country | Link |
---|---|
US (3) | US20040234522A1 (pt) |
EP (1) | EP1222209A2 (pt) |
JP (1) | JP4931310B2 (pt) |
KR (3) | KR100874280B1 (pt) |
CN (1) | CN1279054C (pt) |
AU (2) | AU1095001A (pt) |
BR (1) | BR0015055A (pt) |
CA (1) | CA2389317A1 (pt) |
IL (2) | IL148936A0 (pt) |
MX (1) | MXPA02003897A (pt) |
NZ (1) | NZ531141A (pt) |
WO (1) | WO2001029070A2 (pt) |
ZA (1) | ZA200202468B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100874280B1 (ko) * | 1999-10-20 | 2008-12-18 | 제넨테크, 인크. | T 헬퍼 세포 매개 질환의 치료를 위한 t 세포 분화의조절 |
US7393532B1 (en) | 2000-10-18 | 2008-07-01 | Genentech, Inc. | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
US9738700B2 (en) | 2002-01-18 | 2017-08-22 | Zymogenetics Inc. | ZCYTOR17 heterodimeric cytokine receptor |
US7494804B2 (en) * | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
WO2004069173A2 (en) * | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
BRPI0507776A (pt) * | 2004-02-17 | 2007-07-10 | Schering Corp | métodos de modular a atividade de citocina; reagentes relacionados |
KR20070095949A (ko) * | 2004-12-16 | 2007-10-01 | 제넨테크, 인크. | 자가면역 장애의 치료 방법 |
ES2612383T3 (es) * | 2006-07-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | WSX-1/IL-27 como una diana para respuestas antiinflamatorias |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5009772A (en) | 1989-02-27 | 1991-04-23 | Kerr-Mcgee Corporation | Solvent extraction process |
JPH04503957A (ja) | 1989-03-07 | 1992-07-16 | ジェネンテク,インコーポレイテッド | 脂質とオリゴヌクレオチドの共有結合コンジュゲート |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
JPH04505261A (ja) | 1989-05-10 | 1992-09-17 | スローン―ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ | ポルiiiプロモーターの制御下の転写可能な外来dnaを含む安定的に形質転換された真核細胞 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
JP3720353B2 (ja) * | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
AU2582897A (en) | 1996-03-15 | 1997-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
EP0918858A1 (en) * | 1996-05-10 | 1999-06-02 | Biogen, Inc. | Common gamma chain blocking agents |
US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
KR100874280B1 (ko) * | 1999-10-20 | 2008-12-18 | 제넨테크, 인크. | T 헬퍼 세포 매개 질환의 치료를 위한 t 세포 분화의조절 |
AU2003235833A1 (en) * | 2002-04-26 | 2003-11-10 | Chugai Seiyaku Kabushiki Kaisha | Method of screening agonistic antibody |
ATE506987T1 (de) * | 2002-12-31 | 2011-05-15 | Schering Corp | Il-27 et il-2 pour le traitement du cancer |
KR20070095949A (ko) * | 2004-12-16 | 2007-10-01 | 제넨테크, 인크. | 자가면역 장애의 치료 방법 |
-
2000
- 2000-10-18 KR KR1020077028670A patent/KR100874280B1/ko not_active IP Right Cessation
- 2000-10-18 NZ NZ531141A patent/NZ531141A/en not_active IP Right Cessation
- 2000-10-18 BR BR0015055-0A patent/BR0015055A/pt not_active Application Discontinuation
- 2000-10-18 KR KR1020087017088A patent/KR20080068767A/ko not_active Application Discontinuation
- 2000-10-18 EP EP00972264A patent/EP1222209A2/en not_active Withdrawn
- 2000-10-18 MX MXPA02003897A patent/MXPA02003897A/es active IP Right Grant
- 2000-10-18 WO PCT/US2000/028827 patent/WO2001029070A2/en active Application Filing
- 2000-10-18 CN CNB008171769A patent/CN1279054C/zh not_active Expired - Fee Related
- 2000-10-18 AU AU10950/01A patent/AU1095001A/en not_active Abandoned
- 2000-10-18 IL IL14893600A patent/IL148936A0/xx unknown
- 2000-10-18 CA CA002389317A patent/CA2389317A1/en not_active Abandoned
- 2000-10-18 KR KR1020027005032A patent/KR100840033B1/ko not_active IP Right Cessation
- 2000-10-18 JP JP2001531868A patent/JP4931310B2/ja not_active Expired - Fee Related
-
2002
- 2002-03-27 IL IL148936A patent/IL148936A/en not_active IP Right Cessation
- 2002-03-27 ZA ZA200202468A patent/ZA200202468B/xx unknown
-
2003
- 2003-09-15 US US10/663,158 patent/US20040234522A1/en not_active Abandoned
-
2006
- 2006-01-27 AU AU2006200374A patent/AU2006200374B2/en not_active Ceased
- 2006-09-29 US US11/537,572 patent/US20070134238A1/en not_active Abandoned
-
2009
- 2009-05-07 US US12/437,452 patent/US20110097325A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL148936A0 (en) | 2002-09-12 |
US20070134238A1 (en) | 2007-06-14 |
WO2001029070A8 (en) | 2001-09-20 |
EP1222209A2 (en) | 2002-07-17 |
ZA200202468B (en) | 2003-06-25 |
JP4931310B2 (ja) | 2012-05-16 |
US20110097325A1 (en) | 2011-04-28 |
WO2001029070A3 (en) | 2002-05-02 |
AU2006200374B2 (en) | 2009-12-10 |
WO2001029070A2 (en) | 2001-04-26 |
US20040234522A1 (en) | 2004-11-25 |
KR20070121855A (ko) | 2007-12-27 |
KR100840033B1 (ko) | 2008-06-19 |
NZ531141A (en) | 2005-07-29 |
AU1095001A (en) | 2001-04-30 |
CN1279054C (zh) | 2006-10-11 |
KR20020048971A (ko) | 2002-06-24 |
CN1409726A (zh) | 2003-04-09 |
IL148936A (en) | 2010-12-30 |
CA2389317A1 (en) | 2001-04-26 |
KR20080068767A (ko) | 2008-07-23 |
JP2003512824A (ja) | 2003-04-08 |
KR100874280B1 (ko) | 2008-12-18 |
PL355284A1 (en) | 2004-04-05 |
MXPA02003897A (es) | 2002-12-13 |
AU2006200374A1 (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zabala et al. | P2X4 receptor controls microglia activation and favors remyelination in autoimmune encephalitis | |
Emmerson et al. | Salivary glands regenerate after radiation injury through SOX2‐mediated secretory cell replacement | |
Graveland et al. | The frequency and distribution of medium-sized neurons with indented nuclei in the primate and rodent neostriatum | |
Papp et al. | Parallel changes in dopamine D 2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine | |
Klarquist et al. | Reduced skin homing by functional Treg in vitiligo | |
Du et al. | Dopamine D3 receptor‐preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons | |
Andres-Mach et al. | Radiation effects on neural precursor cells in the dentate gyrus | |
BRPI0518307A2 (pt) | mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3 | |
Lao et al. | Dopamine D3 receptor activation promotes neural stem/progenitor cell proliferation through AKT and ERK1/2 pathways and expands type‐B and‐C cells in adult subventricular zone | |
Laske et al. | Decreased brain-derived neurotrophic factor (BDNF)-and β-thromboglobulin (β-TG)-blood levels in Alzheimer’s disease | |
BR0009537A (pt) | Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso | |
Ghitani et al. | Excitatory synaptic feedback from the motor layer to the sensory layers of the superior colliculus | |
Zhang et al. | Recombinant growth differentiation factor 11 influences short-term memory and enhances Sox2 expression in middle-aged mice | |
Hauck et al. | Increased numbers of FoxP3‐expressing CD 4+ CD 25+ regulatory T cells in peripheral blood from dogs with atopic dermatitis and its correlation with disease severity | |
Shen et al. | Intravenous administration of Achyranthes bidentata polypeptides supports recovery from experimental ischemic stroke in vivo | |
Teixeira et al. | Immune response in the adipose tissue of lean mice infected with the protozoan parasite Neospora caninum | |
BR0015055A (pt) | Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr | |
Ng et al. | Human central nervous system myelin inhibits neurite outgrowth | |
Bornstein et al. | Multiple sclerosis and experimental allergic encephalomyelitis: specific demyelination of CNS in culture | |
Wang et al. | Reduced oligodendrocyte precursor cell impairs astrocytic development in early life stress | |
Arnold et al. | Acute simian varicella virus infection causes robust and sustained changes in gene expression in the sensory ganglia | |
Zajicek et al. | Cylindromatosis drives synapse pruning and weakening by promoting macroautophagy through Akt-mTOR signaling | |
Tan et al. | Pituitary adenylate cyclase activating peptide deficient mice exhibit impaired thymic and extrathymic regulatory T cell proliferation during EAE | |
Bucher et al. | Local immune cell contributions to fracture healing in aged individuals–A novel role for interleukin 22 | |
Wilms et al. | Regulation of activin A synthesis in microglial cells: pathophysiological implications for bacterial meningitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15V | Prolongation of time limit allowed |
Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 25 (VINTE E CINCO) DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 24, 8O E 13, ART. 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |